BMC Musculoskeletal Disorders (May 2017)

Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study

  • Chul-Won Ha,
  • Yong-Beom Park,
  • Chong-Hyuk Choi,
  • Hee-Soo Kyung,
  • Ju-Hong Lee,
  • Jae Doo Yoo,
  • Ju-Hyung Yoo,
  • Choong-Hyeok Choi,
  • Chang-Wan Kim,
  • Hee-Chun Kim,
  • Kwang-Jun Oh,
  • Seong-Il Bin,
  • Myung Chul Lee

DOI
https://doi.org/10.1186/s12891-017-1591-4
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background This randomized, double-blind, multi-center, non-inferiority trial was conducted to assess the efficacy and safety of a cross-linked hyaluronate (XLHA, single injection form) compared with a linear high molecular hyaluronate (HMWHA, thrice injection form) in patients with symptomatic knee osteoarthritis. Methods Two hundred eighty seven patients with osteoarthritis (Kellgren-Lawrence grade I to III) were randomized to each group. Three weekly injections were given in both groups but two times of saline injections preceded XLHA injection to maintain double-blindness. Primary endpoint was the change of weight-bearing pain (WBP) at 12 weeks after the last injection. Secondary endpoints included Western Ontario and McMaster Universities Osteoarthritis index; patient’s and investigator’s global assessment; pain at rest, at night, or in motion; OMERACT-OARSI responder rate; proportion of patients achieving at least 20 mm or 40% decrease in WBP; and rate of rescue medicine use and its total consumption. Results Mean changes of WBP at 12 weeks after the last injection were −33.3 mm with XLHA and −29.2 mm with HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (−1.9 mm, 10.1 mm) was well above the predefined margin (−10 mm). There were no significant between-group differences in all secondary endpoints. Injection site pain was the most common adverse event and no remarkable safety issue was identified. Conclusions This study demonstrated that a single injection of XLHA was non-inferior to three weekly injections of HMWHA in terms of WBP reduction, and supports XLHA as an effective and safe treatment for knee osteoarthritis. Trial registration ClinicalTrials.gov ( NCT01510535 ). This trial was registered on January 6, 2012.

Keywords